Смертельно опасные лекарства и организованная преступность

78. Suntharalingam G., Perry M. R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD 28 monoclonal antibody TGN 1412. N Engl J Med. 2006; 355: 1018–28.

79. Lenzer J., Brownlee S. An untold story? BMJ. 2008; 336: 532–4.

80. Gøtzsche P. C. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.

81. Danish Medicines Agency. [Danish Medicines Agency’s Performance Contract 2007–2010]. Available online at: www.laegemiddelstyrelsen.dk/db/fi larkiv/6653/resultatkontrakt2007_2010.pdf (accessed 15 August 2008).

82. Okie S. Safety in numbers – monitoring risk in approved drugs. N Engl J Med. 2005; 352:1173–6.

83. Carlsen L. T. [A diffi cult balance]. Tænk + Test. 2003; 32: 30–3.

84. Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.

85. Schwartz L. M., Woloshin S., Welch H. G. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009; 150: 516–27.

86. Woloshin S., Schwartz L. M., Welch H. G. Know your Chances: understanding health statistics. Berkely: University of California Press; 2008.

87. Woloshin S., Schwartz L. M. Think inside the box. New York Times. 2011 July 4.

88. Chren M. M., Landefeld C. S. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.

89. Brennan T. A., Rothman D. J., Blank L., et al. Health industry practices that create confl icts of interest: a policy proposal for academic medical centers. JAMA. 2006; 295: 429–33.

90. Tougaard H., Hundevadt K. [The golden promises of the gynaecologists]. Jyllandsposten. 2004 Jan 18.

91. Fugh-Berman A., McDonald C. P., Bell A. M., et al. Promotional tone in reviews of menopausal hormone therapy after the women’s health initiative: an analysis of published articles. PLoS Med. 2011; 8: e1000425.

92. Singer N. Medical papers by ghostwriters pushed therapy. New York Times. 2009 Aug 4.

93. Rosenberg M. Pfizer’s ghostwritten journal articles are still standing, still bogus. Online Journal. 2010 Feb 23.

94. Gøtzsche P. C. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.

95. Conflicts of interest in biomedical research. Canada’s Voice for Academics. 2003; 50: Feb.

96. Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004; 34: 18–23.

97. Willman D. How a new policy led to seven deadly drugs. Los Angeles Times. 2000 Dec 20.

98. Bindslev J. B., Schroll J., Gøtzsche P. C., et al. Underreporting of confl icts of interest in clinical practice guidelines: cross-sectional study. BMC Med Ethics. 2013; 14: 19.

99. Steinbrook R. Controlling confl ict of interest – proposals from the Institute of Medicine. N Engl J Med. 2009; 360: 2160–3.

100. Zinner D. E., Bolcic-Jankovic D., Clarridge B., et al. Participation of academic scientists in relationships with industry. Health Aff. 2009; 28: 1814–25.

101. Lenzer J. French guidelines are pulled over potential bias among authors. BMJ. 2011; 342: d4007.

102. Clinard M. B., Yeager P. C. Corporate Crime. New Brunswick: Transaction Publishers; 2006.

103. Reuters. Factbox – The 20 largest pharmaceutical companies. 2010 Mar 26. Available online at: www.reuters.com/article/2010/03/26/pharmaceutical-mergers-idUSN2612865020100326 (accessed 17 June 2012).

104. Wikipedia. List of countries by GDP (nominal). Available online at: http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal) (accessed 30 June 2012).

105. Annas G. J. Corporations, profi ts, and public health. Lancet. 2010; 376: 583–4.

106. Thomas K., Schmidt M. S. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. 2012 July 2.

107. Khan H., Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case. ABC News. 2010 April 27.

108. Brynner R., Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.

109. House of Commons Health Committee. The Infl uence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).

110. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283: 373–80.